Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases

Merck (MRK) Tops Q1 EPS by 11c; Bumps Non-GAAP FY15 Outlook

April 28, 2015 7:02 AM EDT

Merck (NYSE: MRK) reported Q1 EPS of $0.85, $0.11 better than the analyst estimate of $0.74. Revenue for the quarter came in at $9.4 billion versus the consensus estimate of $9.04 billion.

Merck narrowed and raises FY2015 Non-GAAP EPS to $3.35-$3.48, versus the consensus of $3.37. Lowers 2015 Full-Year GAAP EPS... More